Biotechnology company ZandCell LLC reported on Tuesday the availability of a fast, reliable and affordable COVID-19 saliva based rapid antigen test kit to be used in airports, governments, states, hospitals, sports events and for healthcare workers.
According to ZandCell, its COVID-19 Rapid Antigen Test rapidly tests to qualitatively detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high accuracy.
The saliva-based ZandCell COVID-19 Rapid Antigen Test is now available in large quantities and can quickly and effectively test patients for the infectious virus and provide immediate results within three to ten minutes.
ZandCell COVID-19 Rapid Antigen Test was CE certified on 11 September and will be available in the US upon EUA FDA approval.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT